Molefy Pharma Presents Its Strategy to Develop New Therapies for Neurodegenerative Diseases Such as ALS
The Spanish company combines pharmaceutical research and development with business capabilities to translate scientific knowledge into new therapeutic opportunities. AP-2, its most advanced program, currently in Phase I, is investigating a new approach to targeting TDP-43 protein dysfunction associated with ALS, with the aim of reversing or curing the disease. Dr. Ana Martínez and Dr. […]
Molefy Pharma’s Research Places the Canary Islands at the Heart of the Fight Against ALS
The company collaborated with Molefy Pharma, the CSIC and the Government of the Canary Islands in an event that brought together experts to address the scientific, care-related and social challenges of Amyotrophic Lateral Sclerosis.
A Canary Islands Company Leads the Clinical Trial of a New Drug to Treat ALS
Following the discovery of several molecules by a CSIC research group, Molefy Pharma will become one of the first organizations worldwide to evaluate the viability of this new therapeutic approach. By Verónica Pavés. Santa Cruz de Tenerife. Originally published by El Día. A company based in the Canary Islands will lead the clinical trial of a promising new treatment aimed […]
Molefy wins the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife
Moley Pharma, a spin-off of the CSIC in collaboration 1with ARQUIMEA dedicated to finding a cure for amyotrophic lateral sclerosis (ALS) through the AP-2 molecule, has won first prize in the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife. The event, held as part of the second edition of Hub Intech, […]
Molefy Pharma Showcased New ALS Research at ENCALS 2025 in Turin
Santa Cruz de Tenerife, 9 de junio de 2025. Molefy Pharma, a biotech company focused on developing innovative therapies for ALS and other neurodegenerative diseases, successfully presented three scientific papers at the ENCALS 2025 Meeting, held in Turin, Italy, reaffirming its commitment to advancing therapeutic innovation in Amyotrophic Lateral Sclerosis (ALS). The European Network to […]